Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | GRM5 | P41594 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954513 | 0.93 | CCR1 (0.52) | CCR1CCR8RECQLHTTNOS3 | |
| SCHEMBL24375836 | 0.83 | HTT (0.43) | CCR1CCR8RECQLHTTNOS3 | |
| SCHEMBL17881711 | 0.83 | HTT (0.43) | CCR1CCR8RECQLHTTNOS3 | |
| SCHEMBL24375611 | 0.83 | HTT (0.43) | CCR1CCR8RECQLHTTNOS3 | |
| SCHEMBL5343791 | 0.81 | NOS2 (0.42) | CCR1CCR8RECQLHTTNOS3 | |
| SCHEMBL102150 | 0.76 | CCR1 (0.50) | CCR1CCR8RECQLHTTNOS3 | |
| SCHEMBL14577729 | 0.74 | CCR1 (0.48) | CCR1CCR8RECQLHTTNOS3 | |
| SCHEMBL2019306 | 0.74 | CCR1 (0.48) | CCR1CCR8RECQLHTTNOS3 | |
| SCHEMBL17086669 | 0.74 | HTT (0.40) | CCR1CCR8RECQLHTTNOS3 | |
| SCHEMBL12915375 | 0.74 | HTT (0.40) | CCR1CCR8RECQLHTTNOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8617723-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2013-12-31 | — | — | US | disclosed |
| US-20110012100-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| EP-2254896-A1 | METAL COMPLEXES | Merck Patent GmbH (DE) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009118087-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110012100-A1 | METAL COMPLEXES | AP1M1, AP3M1, SOD1 | CCR1 1608/4885CCR8 3259/4885RECQL 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.